Clinical Trials
5
Active:3
Completed:2
Trial Phases
1 Phases
Phase 3:4
Drug Approvals
1.9k
CANADA:925
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- 93
- Next
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 3
4 (100.0%)The Evaluation of Injection Site Pain and Adherence in Patients Switching from a Low to High Concentration Adalimumab (AVT-02) Across Multiple Indications.
Active, not recruiting
- Conditions
- Crohn DiseaseAnkylosing SpondylitisPlaque PsoriasisHidradenitis SuppurativaUlcerative ColitisPsoriatic ArthritisRheumatoid Arthritis
- Interventions
- Biological: AVT02 (Alvotech Biosimilar to Adalimumab)
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Jamp Pharma Corporation
- Target Recruit Count
- 600
- Registration Number
- NCT05913817
- Locations
- 🇨🇦
JAMP Pharma Corporation, Montréal, Quebec, Canada
News
No news found